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Editorial
Unexpected drug failure is a lack of therapeutic effect, which is not
expected based on the characteristics of the drug and patient.
Essentially, it may occur either for interactions (with other drugs or
foods) or for biopharmaceutical issues. The risk arising from
interactions is generally well characterised and physicians are well
aware of it, and the importance of reporting cases of failure due to
interactions is obvious. Less is known about the mechanisms and
potential risk deriving from biopharmaceutical problems, and we will
therefore focus on this issue. Biopharmaceutics describes the influence
of the physical/chemical properties of the drug and drug product on
the rate and extent of systemic drug absorption. Because after oral
administration of solid pharmaceutical forms drugs must dissolve in
gastrointestinal fluids before being absorbed through the intestinal
epithelium, biopharmaceutical problems essentially arise from an
insufficient dissolution performance. A typical situation where an
insufficient dissolution may cause unexpected drug failure is when a
patient is switched from one drug product to a different product.
Different drug products with the same active substance may differ in
manufacture and excipient composition.
These differences may cause a different dissolution performance in
vivo, leading to different rate and/or extent of absorption. Therefore,
drug products are considered to be interchangeable only if their
bioequivalence has been demonstrated through pharmacokinetic
studies in vivo and/or comparative dissolution studies in vitro.
However, the bioavailability of two bioequivalent drug may differ, even
though only to a limited extent, and this may lead to unexpected drug
failure following a switch, appearing as sudden loss of a full therapeutic
effect in patients previously responding to the drug. An impressive case
report described the consequences of switching 25 patients with a
stable response to branded clozapine (Clozaril®) to a generic clozapine
[1]. Seven of the 25 patients experienced a relapse, defined as the re-
emergence of previously controlled psychotic symptoms that either
required hospitalization or for which hospitalization was considered.
Six additional patients experienced mild exacerbations of symptoms.
Thus, 52% of the 25 patients showed at least some sign of deterioration
after the switch to the generic formulation of clozapine. In the 7
patients experiencing a relapse, no improvement was achieved by
increasing the dose of generic clozapine. However, all 7 patients rapidly
improved when Clozaril® was reinstated. A clinical study investigating
the clinical effects of a randomized switch of patients from Clozaril® to
generic clozapine confirmed that the switch was associated with an
increased risk of therapeutic failure [2]. Generic clozapine had been
authorised based on a bioequivalence study performed in healthy
volunteers using a sub-therapeutic dose of 12.5 mg because of safety
concerns. The assumption was that the bioequivalence would also be
valid with the much higher therapeutic doses. These and other reports
indicated that this was not the case and eventually led the FDA to
change the protocol of bioequivalence studies for generic clozapine,
which currently prescribes the use of a therapeutic dose of 100 mg in
patients. Nowadays, generic clozapine is considered to be
therapeutically equivalent to Clozaril® [3].
The risk of therapeutic failure as a consequence of switching during
therapy is considered to be particularly relevant for anti-epileptic
drugs (AEDs) [4,5]. AEDs are considered to be narrow therapeutic
index drugs, because even small deviations in bioavailability have the
potential to result in loss of seizure control in some patients. Therefore,
while initiating an innovator or generic antiepileptic drug will provide
similar efficacy, tolerability, and safety, switching from one form to the
other may be associated with therapeutic failure. There have been
several reports of breakthrough seizures after switching from one
version of an AED to another, (whether the switch was brand-to-
generic, generic-to-brand, or generic-to-generic. on generic
substitution) [4]. Subsequent pharmacoepidemiological studies found
that generic substitution AEDs was associated with significantly
greater risk of epilepsy-related medical events and requiring urgent
seizure-related care [6,7].
As a result of these reports and studies, Epilepsy Foundation has
developed serious concerns about policies that permit or require AED
substitutions without the consent of the doctor and patient [8].
Epilepsy Foundation has asked the FDA to “consider issuing a limited
advisory to patients and physicians regarding potential problems with
switching between different medication formulations (whether generic
to generic or generic to brand) for some people with epilepsy”.
Specifically, Epilepsy Foundation hopes that the FDA would at least
advise physicians that they should consider monitoring the blood
levels of patients before making any subsequent changes in the
patient's treatment regimen and that, for some patients, no switching
should occur except with the oversight, monitoring, and consent of the
physician and patient. These concerns about switch are shared by other
scientific associations.
The Italian League against Epilepsy (LICE) even issued a guideline
not recommending the switch in patients with a complete clinical
control. From a regulatory perspective the issue of switching is very
complex. In fact, in 1999 the FDA issued a draft Guidance introducing
the concept of ‘switchability’, and the related criteria for bioequivalence
studies, but the Guidance was later substituted with a new one,
currently in use, which does not address directly the problem of
switchability. However, regulatory agencies have revised their
bioequivalence guideline in order to reduce the risk of therapeutic
failure for narrow therapeutic index (NTI) drugs. The current EU and
Canadian Guidelines on bioequivalence have introduced the concept
that the bioequivalence interval should be tightened to 90-111%
(instead of the usual 80.0-125.0% interval) for NTI drugs. The FDA has
published product-specific bioequivalence draft guidance for two NTI
drugs (warfarin sodium tablet and tacrolimus capsule) recommending
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to apply a study protocol and statistical approach different from those
generally used to demonstrate the bioequivalence.
There may be a risk of therapeutic failure also when a patient is
switched from one formulation to a different formulation of a same
drug product. Different formulations of the same drug product differ
in their pharmaceutical form, for example tablets vs. oral solution, and
may have a different bioavailability. A case of serious therapeutic
failure caused by switching form one formulation to another has been
recently reported by the FDA [9]. The antifungal drug Noxafil®
(posaconazole) is available in two oral formulations, delayed-release
tablet and oral suspension, with the tablet having a higher
bioavailability than the suspension.
In the case report, a patient was taking Noxafil delayed-release
tablets for prophylaxis of invasive Aspergillus and Candida infections,
but the pharmacy replaced the tablets with the oral suspension. The
patient was reported to have later died from a stroke related to an
invasive Aspergillus infection. This and other reports led the FDA to
release a Safety Communication cautioning about dosing errors when
switching between the different oral formulations. In addition, the
manufacturer of Noxafil® revised the prescribing information and the
patient information in the drug label to alert patients and their health
care professionals that the two oral formulations of Noxafil® cannot be
substituted for each other.
It should be considered that unexpected failure due to
biopharmaceutical issues is not necessarily related to a switch but may
also arise in patients with a particular gastrointestinal physiology. An
explicative example is given by the report of Yamamoto [10], who
observed that three patients with hypothyroidism did not achieve the
therapeutic goal, i.e., normalization of serum thyrotropin (TSH)
despite taking high doses of levothyroxine (LT4) as tablets. History of
gastrointestinal illnesses, signs and symptoms of such a condition, and
concurrent medications known to affect the absorption of LT4 from
the gut were absent. The patients’ TSH levels normalized when the
tablets were taken after being pulverized. This clearly indicates that in
these 3 patients the drug dissolved too slowly from the tablets, thus
leading to insufficient bioavailability.
Pulverization increased the rate of dissolution and, consequently,
the bioavailability. Noteworthy, Yamamoto reported that during the
period of the clinical study with the 3 patients, he treated 105 adult
patients with primary hypothyroidism, with no problems in
normalizing their TSH with standard LT4 doses, indicating that the
problem arose from the interaction between the particular
physiological characteristics of some patients and the pharmaceutical
performance of the drug product. Dr. Yamamoto concluded that for
patients with hypothyroidism that require more than the optimal dose
of 200 mg/day in order to keep the serum TSH levels within the
normal ranges, pulverization of the tablets is worth consideration. It
could be could be anticipated that a liquid LT4 formulation should
perform even better than pulverized tablets. Liquid formulations of
LT4 are now marketed, and clinical trials suggest that they may
actually be superior to the tablets in maintaining the euthyroid state
[11].
In conclusion, physicians, pharmacists, and patients should always
keep in mind the possibility that unexpected drug failure may be due
to biopharmaceutical issues. Reporting these cases of unexpected drug
failure may provide valuable information for finding a solution for not-
responder patients. As we have seen, reporting unexpected drug
failures can also lead to development of revised guidelines or
recommendations from regulatory agencies or scientific associations,
thus increasing the safe use of drugs. In some cases, it may even concur
to encourage pharmaceutical companies to develop new drug
formulations, as in the case of liquid LT4.
References
1. Mofsen R, Balter J (2001) Case reports of the reemergence of psychotic
symptoms after conversion from brand-name clozapine to a generic
formulation. Clin Ther 23: 1720-1731.
2. Kluznik JC, Walbek NH, Farnsworth MG, Melstrom K (2001) Clinical
effects of a randomized switch of patients from clozaril to generic
clozapine. J Clin Psychiatry 62 Suppl 5: 14-17.
3. Bobo WV, Stovall JA, Knostman M, Koestner J, Shelton RC (2010)
Converting from brand-name to generic clozapine: A review of
effectiveness and tolerability data. Am J Health Syst Pharm 67: 27-37.
4. Crawford P, Feely M, Guberman A, Kramer G (2006) Are there potential
problems with generic substitution of antiepileptic drugs? A review of
issues. Seizure 15: 165-176.
5. Talati R, Scholle JM, Phung OP, Baker EL, Baker WL, et al. (2012) Efficacy
and safety of innovator versus generic drugs in patients with epilepsy: a
systematic review. Pharmacotherapy 32: 314-322.
6. Labiner DM, Paradis PE, Manjunath R, Duh MS, Lafeuille MH, et al.
(2010) Generic antiepileptic drugs and associated medical resource
utilization in the United States. Neurology 74: 1566-1574.
7. Zachry WM III, Doan QD, Clewell JD, Smith BJ (2009) Case-control
analysis of ambulance, emergency room, or inpatient hospital events for
epilepsy and antiepileptic drug formulation changes. Epilepsia 50: 493-500.
8. Epilepsy Foundation comments on generic drugs user fee amendments.
9. Drug Safety Communication-Dosing Errors when Switching between
Different Oral Formulations; Label Changes Approved.
10. Yamamoto T (2003) Tablet formulation of levothyroxine is absorbed less
well than powdered levothyroxine. Thyroid 13: 1177-1181.
11. Negro R, Valcavi R, Agrimi D, Toulis KA (2014) Levothyroxine liquid
solution versus tablet for replacement treatment in hypothyroid patients.
Endocr Pract 20: 901-906.
 
Citation: Romanelli L, Mhillaj E, Cuomo V (2016) The Importance of Reporting Unexpected Drug Failure. J Pharmacovigil 4: e148. doi:
10.4172/2329-6887.1000e148
Page 2 of 2
J Pharmacovigil
ISSN:2329-6887 JP, an open access journal Volume 4 • Issue 1 • 1000e148
